Match!
Raj Sengupta
Royal National Hospital for Rheumatic Diseases
Physical therapyAnkylosing spondylitisDiseaseDiabetes mellitusMedicine
110Publications
11H-index
349Citations
What is this?
Publications 110
Newest
#2Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
PURPOSE OF REVIEW Physical therapy is recommended for the management of axial spondyloarthritis (axSpA) with the focus of promoting physical activity and prescribing exercise within four domains, outlined recently by the European League against Rheumatism (EULAR): aerobic, resistance, flexibility and neuro-motor exercise. There is an increasing evidence base to support physical therapy interventions in axSpA. RECENT FINDINGS We present evidence supporting the use of exercise as treatment for pat...
Source
#1Rosie Barnett (University of Bath)
Last. Raj Sengupta (University of Bath)H-Index: 11
view all 5 authors...
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease, characterised by fluctuating periods of flare and remission. Flare is a multidimensional change of disease state; whereby flare definitions have previously been formulated using validated composite indices, or through qualitative retrospective investigation of flare states. Smartphone technologies for tracking disease symptoms provide unique, daily insights into self-reported individual flare experience, and may prese...
Source
#1Elizabeth Reilly (Royal National Hospital for Rheumatic Diseases)H-Index: 2
#2Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
: Social media usage by back pain patients is a new and developing area. Analysing patterns of this online activity offers a new way to understand our patients' concerns and behaviour around disease. Large volume data can be evaluated on a scale not feasible through alternative methods. A cross sectional review of specific terms relating to 'back pain' (BP) and 'ankylosing spondylitis' (AS) were tracked internationally on popular websites, blogs and boards over two 3 month periods, in 2016 and 2...
Source
#1Sinead MaguireH-Index: 1
#2Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
Last. Finbar D. O’SheaH-Index: 14
view all 3 authors...
Axial spondyloathritis (axSpA) treatment with biologic DMARDs was previously focused around anti-TNF agents. Significant advances in research have led to new therapeutic options, such as secukinumab, an IL-17 inhibitor, which has been approved for the treatment of axSpA. Two other biologic agents that are already licensed for rheumatoid and psoriatic arthritis, tofacitinib and ixekizumab, have demonstrated improved outcomes in axSpA. Several newer agents have been developed to inhibit IL-17, IL-...
Source
#1Elizabeth Reilly (University of Bath)H-Index: 2
#2Anita McGrogan (University of Bath)H-Index: 10
Last. Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
view all 3 authors...
Source
#1Thomas A Ingram (University of Bath)
#2Peter C. Rouse (University of Bath)H-Index: 11
Last. Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
view all 5 authors...
Source
#1Elizabeth ReillyH-Index: 2
#2Anita McGrogan (EPSRC: Engineering and Physical Sciences Research Council)H-Index: 10
Last. Raj SenguptaH-Index: 11
view all 3 authors...
#1Saion Chatterjee (Royal National Hospital for Rheumatic Diseases)
#2Helena Marzo-Ortega (NIHR: National Institute for Health Research)H-Index: 49
Last. Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
view all 5 authors...
Source
#1Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 11
#2Lianne S. Gensler (UCSF: University of California, San Francisco)H-Index: 19
Last. Atul Deodhar (OHSU: Oregon Health & Science University)H-Index: 34
view all 10 authors...
Source
#1Liz Van RossenH-Index: 1
#2Cathal Boyle (Royal National Hospital for Rheumatic Diseases)H-Index: 1
Last. Andrew KeatH-Index: 3
view all 10 authors...
Source
12345678910